Intraperitoneal chemotherapy

Howell, S. B., and Zimm, S. (1988). Intraperitoneal chemotherapy Application to upper gastrointestinal neoplasms, Acta Chir. Scand. Suppl., 541, 16-21. 

Markman, M., Cleary, S., Lucas, W. E., and Howell, S. B. (1985). Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity, J. Clin. Oncol., 3, 925-931. 

Colchicine (a drug used in treatment of gout) and vinblastine (a cancer chemotherapy agent) may decrease liver uptake of americium. In rats that received an intraperitoneal injection of either colchicine and vinblastine prior to an intravenous or intramuscular injection of americium citrate, liver uptake of americium was lower, relative to controls, and kidney and skeletal americium uptake were higher (Seidel 1984, 1985). The effect is thought to involve disruption of hepatic microtubule formation, which is critical to the formation and intracellular processing of lysosomes, the initial site of accumulation of americium in the liver. 

IPHC, Intraperitoneal hyperthermic chemoperfusion/chemotherapy MMC, Mitomycin C IP, Intraperitoneal SOD, Superoxide dismutase Nd YAG, Neodymium-doped yttrium aluminium garnet Nd Y3A15012 NIR, Near infrared FITC, Fluorescein isothiocyanate PEG, Polyethylene glycol FA, Fohc acid CDDP, Cisplatin TEM, Transmission electron microscopy... 

Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P (2007) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy experience with 501 procedures. Journal of the American College of Surgeons 204 943-953. 

Stewart JH, Shen P, Levine EA (2005) Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy current status and future directions. Annals of Surgical Oncology 12 765-777. 

Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10 112-122. 

Intraperitoneal chemotherapy has been under investigation for many years and accumulating positive indicators were recently reinforced by the phase III Gynecology Oncology Group study [GOG 172] (see Armstrong et al., 2006). This study randomized optimally debulked patients to either intravenous paclitaxel and cisplatin or to intravenous paclitaxel plus intraperitoneal paclitaxel and cisplatin. After a median follow-up of four years an overall survival advantage for the IP arm of 65.6 versus 49.7 months was seen. 

Speyer, J. L. (1985), The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies, Semin. Oncol., 12, 23. 

Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy A comparison with systemic chemotherapy. Cancer Res 1989 49 3380-4. 

Intraperitoneal drug administration is not common. It is used pedominantly to administer compounds during preclinical discovery and development. Its clinical use is generally limited to chemotherapy for tumors with peritoneal involvement. 

Abe R, Akiyoshi T, Baba T. Two-route chemotherapy using cisplatin and its neutraUzing agent, sodium thiosulfate, for intraperitoneal cancer. Oncology 1990 47(5) 422-6. 

Markman M. Intraperitoneal chemotherapy. Crit Rev Oncol Hematol 1999 31 239-246. 

Vermorken JB. The role of intraperitoneal chemotherapy in epithelial ovarian cancer. Int J Gynecol Cancer 2000 10(Suppl l) 26-32. 

Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994 54 338-344. 

Piver MS, Redo FO, Baker TR, Driscoll D. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer. Cancer 1994 73 1693-1698. 

Schneider JG. Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 1994 21 195-212. 

Brandner P, Neis KJ. Use of an implantable catheter system for intraperitoneal chemotherapy in ovarian cancer. Artif Organs 1994 18 328-330. 

This laboratory is investigating the use of anti-drug antibodies within an inverse targeting strategy that attempts to increase the pharmacokinetic and therapeutic selectivity of intraperitoneal chemotherapy. The approach combines i.p. chemo-... 

Muggia Fm. Russell CA. New chemotherapies for ovarian cancer systemic and intraperitoneal podophyllotoxins Cancer 1991 67(suppl 1) 225—23... 

Not every solid lesion in a postoperative patient means ovarian cancer recurrence. The combination of CA-125 and a baseline imaging study usually aids in the differential diagnosis. Postoperative hematomas, adhesions between bowel loops, or locahzed trapped fluid may mimic recurrent disease. Benign forms of diffuse peritoneal thickening such as a result of postoperative inflammatory complications or bacterial peritonitis cannot be differentiated from peritonitis carcinomatosa. Furthermore, chemical peritonitis following intraperitoneal chemotherapy also results in diffuse peritoneal thickening [32]. 

---